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Abstract
Background: Insulin-like-growth factor II (IGF II) has been implicated in the pathogenesis of neoplasm of different
tissues, including liver of rats and men. This growth factor is believed to exert its effect during cellular proliferation.
During the process of development of hepatocellular carcinoma (HCC), different hepatic altered foci appear. They are
believed to be the putative precursors of HCC in rats and in men. Thus, to study the role of the gene in a defined model
of hepatocarcinogenesis was the target to elucidate its role in various cancer phenotypes during the entire development
stage of cancer, right from earlier preneoplastic lesions to HCC
Methods: Antisense in situ hybridization technique was used here to characterize the type(s) of foci in which IGF II
mRNA had expressed during the development of hepatocarcinogenesis-induced by diethylnitrosamine and promoted by
phenobarbital in rats. Various focal lesions have been categorized depending on the stages and sizes along with IGF II
expression patterns in them. Immunohistochemical detection for proliferating cell nuclear antigen (PCNA) was made to
detect the role of the gene in preneoplastic and neoplastic cellular proliferation.
Results: IGF II expression was located in the glycogen-storage acidophilic cell foci maximally followed by mixed cell
lesions and the least in basophilic lesions. The expression of IGF II was found to be predominant in the HCC. The
expression of gene was also located at the peripheral cells of spongiosis hepatis which are believed to be the precursor
of ito cell carcinoma. It was noted that there is a direct correlation between IGF II expression and Immunohistochemical
detection for PCNA.
Conclusion: It may be concluded that IGF II gene expression plays an important role during the development of
neoplasia and the gene expresses in the sequence of events leading from glycogen-rich-acidophilic lesions to glycogen
poor basophilic lesions to HCC with an expression pattern of “high-low-high” in terms of degree of expression.
Moreover, the essential role of the gene at the immediate initiation stage of carcinogenesis (first few weeks) and during
HCC development cannot be ignored. Thus this expression can be used as a suitable marker for very early detection of
the cancerous process and can save numbers of future cancer victims by very early detection of this disease.
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Background
Insulin-like-growth factor II (IGF II)b [somatomedin A ] is
a mitogenic polypeptide having structural similarity to
proinsulin and insulin-like-growth factor I (IGF I)
[somatomedin C] [1,2]. IGF II is known to be widely dis-
tributed in various fetal and neonatal human and rat tis-
sues, including liver [3-5], but restricted in the adult rat
tissues [6], except brain [7]. It has also been implicated in
the pathogenesis of neoplasm of different tissues, includ-
ing liver of rats and men [8-11]. The growth factor is
believed to exert their effect during cellular proliferation
through endocrine, autocrine and paracrine mechanisms
[12]. In breast cancer epithelial cells, IGFII was reported to
serve as autocrine growth stimulus and IGFII overexpres-
sion was suggested to be capable of mediating malignant
progression [13]. Expression of IGFII in rodents remains
high around birth and becomes undetectable within three
weeks [14]. But the reactivation of this gene has been
reported in variety of neoplasms including HCC in rats.
IGF II expression has been shown to be reactivated during
progression of neoplastic nodules to HCC [15]. IGFII
reactivation was reported to be a common phenomenon
in hepatocarcinogenesis irrespective of species and the
process of hepatocarcinogenesis [11]. The reactivation of
endogenous IGF II was suggested to exert a growth stimu-
latory effect via IGFI and IGFII/mannose 6 phosphate
receptors [16]. It was stated that IGFII might trigger a pro-
liferating signal through hybrid insulin/IGFI receptors
stimulated by exogenous IGF [17]. Carcinogen treatment
may generate IGFII microenvironment in preneoplastic
foci that lead to selective growth advantage for this cell.
Chemical hepatocarcinogenesis is a multistep and com-
plex process and is a favorite model in rat to study the
mechanism of transformation of a normal cell to malig-
nant population(s) [18]. During the process of develop-
ment of HCC from the normal hapatocytes, hepatic
altered foci appear. These foci are the putative precursors
of HCC in rat, and probably in man [19,20]. Depending
on the morphological and biochemical hepatocellular
changes during the process of development from normal
hepatocytes to HCC induced by various chemical carcino-
gens, radiation, hormones, chronic viral hepatitis and
transgenic manipulation in rodents, three main altered
hepatocellular lesions-the glycogenotic, mixed cell and
basophilic cell lesions have been distinguished [21]. The
predominant sequence of cellular changes starts with gly-
cogenotic clear and acidophilic (smooth endoplasmic
reticulum- rich) hepatocytes and progresses through inter-
mediate phenotypes in mixed cell populations to glyco-
gen-poor, homogeneously basophilic (ribosome -rich)
cellular phenotypes prevailing in undifferentiated HCC.
Elevated levels of IGF II gene and protein expression have
been found in a wide range of human and rodent tumors
[8-10]. IGF II has been claimed to be one of the most
important growth factors, playing role during the
Quantification of DIG-labeled sense and antisense IGFII  mRNA by spot test against standard labeled mRNA (Boe- hringer-Mannheim RNA detection kit) Figure 1
Quantification of DIG-labeled sense and antisense IGFII 
mRNA by spot test against standard labeled mRNA (Boe-
hringer-Mannheim RNA detection kit).
Detection of DIG-labeled IGFII sense and antisense mRNA  (860 bp) using gel electrophoresis Figure 2
Detection of DIG-labeled IGFII sense and antisense mRNA 
(860 bp) using gel electrophoresis. Lane 1; DIG-labeled sense 
IGFII mRNA, Lane 2; DIG-labeled antisense IGFII mRNA.Journal of Carcinogenesis 2005, 4:12 http://www.carcinogenesis.com/content/4/1/12
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progression of neoplasm [22]. But the advent of IGF II
gene expression during the development of neoplasia has
remained to be elucidated. Antisense in situ hybridization
technique has been used here to explore the type(s) of foci
in which IGF II mRNA is expressed at the stages of neo-
plastic conversion of hepatocytes during diethylnitor-
samine (DENA)-induced and phenobarbital promoted
hepatocarcinogensis in Sprague-Dawley rats.
Materials and methods
Experiments were conducted on the hepatic tissues of
male Sprague-Dawley rats (purchased from the Indian
Institute of Chemical Biology, Kolkata, India). The initial
body weights of the animals were approximately 130 g.
They were maintained under constant temperature
(22°C) and humidity (55%RH) conditions and were fed
basal diet [23] and had free access to water. Animals were
divided in four groups-Group A (having 15 animals),
group B, C and D (having 10 animals in each of the three
groups). Group A animals were normal untreated ani-
mals. Group B, C and D animals were carcinogen treated
groups. All carcinogen treated animals were treated with
DENA, 200 mg/kg body weight, intraperitoneally at the
start of the experiment, i.e., day zero. Group C and D ani-
mals were promoted with 0.05 % phenobarbital in basal
diet [24]. Group B animals were sacrificed at the 8th week
to study earlier preneoplastic lesions, group B animals
were sacrificed at 22nd  weeks to study mixed and
basophilic lesions and group C animals were sacrificed at
36th week as HCC development are reported to take place
between 32–36 weeks [25]. In each case five normal con-
trol animals were sacrificed with the respective treated
groups B, C and D for comparison. All animals were unfed
for 12 h before they were sacrificed by cervical dislocation
and the animals were sacrificed between 9 and 10 a.m.
The livers were removed, sliced (5–10 mm thick) and
were snap-frozen in isopentane precooled with liquid
nitrogen at – 150°C. The tissues were stored at – 80°C
until further used.
Serial sections were prepared from the frozen materials
with a Reichert-Jung microtome. They were studied histo-
chemically by periodic acid Schiff reaction, toluidine blue
and hematoxylin-eosin to detect different hepatic altered
foci (26, 27). Preneoplastic lesions were eventually
divided into three categories in accordance with their
respective size and the total area of the occupied liver
parenchyma (<1 mm, >1 mm-<3 mm, >3 mm) as
described previously [28]. These serial sections were used
for  in situ hybridization with sense and anitsense
digoxigenin labeled mRNA probes of IGF II and immuno-
histochemical reaction for proliferating cell nuclear antigen
(PCNA).
In vitro transcription of Digoxigenin (DIG)-labeled sense 
and antisense IGF II mRNA
A 860 base pair (bp) coding region fragment from rIGF II
cDNA extended between EcoRI- EcoRI ploylinker site of
pGEM-4 vector (Source: H. Hacker, DKFZ, Germany,
obtained from A Riccio, Universita degli studi di Napoli
Federico II, Napoli, Italy) was transformed into XL1-blue
E.coli competent cells. The plasmid was also religated and
propagated in the competent cells to obtain the opposite
orientation of the 860 bp coding fragment of rIGF II
cDNA. SP6-RNA polymerase was used to generate both
sense and anitsense riboprobes from Xba I linearized plas-
mids of the opposite orientation. In vitro transcription was
conducted, using digoxigenin (DIG)-RNA labeling Kit
from Boehringer-Mannheim, Mannheim, Germany. The
concentrations of the sense and antisense probes were
estimated by using Nucleic Acid Detection Kit (Boe-
hringer- Mannheim, Mannheim, Germany). The method
is based upon the comparison between the colour inten-
sities of slot blots and DIG labeled standard (Boehringer-
Mannheim, Mannheim, Germany) (Figure 1) and the
experimental riboprobes. By electrophoresing the probes
on formaldehyde containing 1% agarose gel the purity of
the labeled probes were checked (Figure 2).
Table 1: Incidences, numbers and size distributions of preneoplastic lesions (glycogen-storage, mixed cell and basophilic type) in the 
hepatic tissues of male Sprague-Dawley rats in different experimental groups (B, C and D).
Group No. of rats with 
preneoplastic 
lesions/Total 
numbers of rats
Incidences (%) Numerical 
densities of 
preneoplastic 
lesionsa,b
Size distributions of preneoplastic lesions (% of total 
numbers)
<1 mm >1 mm-<3 mm >3 mm
B 10/10 100 412 ± 28 81 19 -
C 10/10 100 968 ± 16 52 44 4
D 10/10 100 1498 ± 33 20 48 32
a Numerical density, expressed in number per cm3 of hepatic tissue
b Each value represent mean of 10 rats per group ± SDJournal of Carcinogenesis 2005, 4:12 http://www.carcinogenesis.com/content/4/1/12
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Table 2: Expression of IGF II gene in different types of preneoplastic hepatic altered focal lesions (HAF) as well as carcinoma in hepatic 
tissues of the experimental animals (group B, C and D)
Types of HAF which expressed IGF II gene Numbers of rats with HAF and/or HCC per 
total no of animals
Number of IGF II expressed lesions/100 
respective HAF lesions
Glycogen-storage focal lesion 10/10 98 ± 2.98a,*
Mixed cell focal lesion 10/10 74 ± 8.26a,*
Basophilic cell focal lesion 10/10 05 ± 2.68a,NS
Hepatocellular carcinoma 7/10 95 ± 4.02%b,*
a Mean ± SD (n = 10)
b Mean ± SD (n = 7)
* P < 0.001
NS- Non-significant
Glycogen storage foci (shown by yellow arrows) in rat hepatic tissue with Periodic Acid Schiff reaction, ×100 Figure 3
Glycogen storage foci (shown by yellow arrows) in rat hepatic tissue with Periodic Acid Schiff reaction, ×100.Journal of Carcinogenesis 2005, 4:12 http://www.carcinogenesis.com/content/4/1/12
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Detection of IGF II mRNA by In situ hybridization
In situ hybridization was conducted on 6 µm cryosections
of the liver samples by using a modified procedure of
Braissant and Walhi [29]. The cryosections were first fixed
at 50°C for 30 seconds on a hot plate and delipidified
with chloroform for 5 min whenever necessary. The sec-
tions were then fixed in 4% paraformaldehyde in phos-
phate buffer saline, pH 7.4, (PBS) for 1 hr. The slides were
then treated with PBS containing active DEPC (diethyl
pyrocarbonate) for 30 min followed by a wash of 4 × SSC
of 15 min. Prehybridization was conducted using hybrid-
ization buffer (mentioned below) except dextran sulphate
and Denhardt's solution for 1 hr. at 52°C. This was fol-
lowed by hybridization at 50°C overnight in a humid
chamber. Every 10 ml of hybridization buffer contained 5
ml deionized formamide, 2.4 ml DEPC treated water, 2
ml 20 × SSC, pH 7.0, 1 g dextran sulphate, 200 µl 50 ×
Denhardt's solution, denatured yeast t-RNA (10 mg/ml)
400 µl and denatured salmon sperm DNA (10 mg/ml) µl
along with respective probes denatured by heating at
80°C for 3 min., followed by immediate cooling on ice.
After hybridization, sections were washed in 2 × SSC at
room temperature (RT) for 30 min, then again with 2 ×
SSC at 60°C, for 30 min. This was followed by 1 × SSC for
30 min and 0.1 × SSC for 1 hr, at 60°C with a frequent
moderate shaking. After the stringency wash, the slides
were incubated with Tris-NaCl buffer, pH 7.5 containing
0.5% blocking agent (Boehringer-Mannheim, Mannheim,
Germany) at RT on a shaking platform with a low speed.
Sections were then incubated with anti-DIG-polyclonal
antibody conjugated with alkaline phosphatase (Boe-
hringer-Mannheim, Mannheim, Germany) (1:5000) in
Tris-NaC1 buffer, pH 7.5 for 2 hr at RT on the shaking
platform with a low speed. After incubation, sections were
washed with washing buffer (Tris-NaC1 buffer, pH 7.5,
containing 0.3% tween 20) for 10 min at RT. This was
Mixed cell focal lesion (shown by green arrows) and basophilic lesion (shown by blue arrows) in DENA treated rat liver, ×100 Figure 4
Mixed cell focal lesion (shown by green arrows) and basophilic lesion (shown by blue arrows) in DENA treated rat liver, ×100.Journal of Carcinogenesis 2005, 4:12 http://www.carcinogenesis.com/content/4/1/12
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followed by two 15 min washes with Tris-NaC1 buffer,
pH 7.5. the section were equilibrated with detection
buffer (100 mM Tris-HC1, 100 mM NaC1 and 50 mM
MgC12,6H2O), pH 9.5 for 5 min and staining was done
using nitroblue tetrazolium/ bromochloroindolylphos-
phate (NBT/BCIP) in detection buffer. Counter staining
was also done occasionally.
Immunohistochemical detection for proliferating cell 
nuclear antigen
PCNA was demonstrated by following the methods of
Enzmann et al. [30] and Bannasch et al [31]. Briefly 6 µm
cryostat sections were air-dried after fixation in acetone
for 10 min followed by a treatment with 2% H2O2 in
methanol to block endogenous peroxidases. Then the
sample was incubated in 3% bovine serum albumin for
30 min to prevent unspecific reactions followed by incu-
bation with mouse monoclonal antibody to PCNA,
diluted 1:1600 (PC10 Dako), overnight at 4°C. PCNA
positive nuclei were identified by using alkaline phos-
Hepatic section of DENA treated experimental animals  showing glycogen storage foci with PAS staining, ×100 Figure 5
Hepatic section of DENA treated experimental animals 
showing glycogen storage foci with PAS staining, ×100.
IGFII mRNA expressed glycogen storage lesion detected with Digoxigenin-labeled antisense IGFII, mRNA ×100 Figure 6
IGFII mRNA expressed glycogen storage lesion detected with Digoxigenin-labeled antisense IGFII, mRNA ×100.Journal of Carcinogenesis 2005, 4:12 http://www.carcinogenesis.com/content/4/1/12
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phatase labeled streptavidine-biotin complex (Dako
LASB2 Kit, AP). Then the sections were stained with new-
fuschin and Myer's haemetoxylin.
IGF II mRNA positive foci were estimated in randomly
selected areas of each section containing hepatic altered
foci from experimental animals. The results were statisti-
cally evaluated using ANOVA followed by Fisher's exact
Test otherwise mentioned.
Results
The morphometric determination of the focal lesions
showed that incidences of preneoplastic lesions (i.e. gly-
cogen storage foci/acidophilic foci [Figure 3], mixed cell
focal lesions and basophilic focal lesions [Figure 4] were
100% in group B, C and D animals. The numerical densi-
ties and size distributions of preneoplastic lesions were
depicted in Table 1. Average numerical density was found
to be maximum (1498 ± 33 per cm3 of hepatic tissue) in
case of group D animals, which was followed by group C
(968 ± 16 per cm3 of hepatic tissue) and group B (412 ±
28 per cm3 of hepatic tissue) animals. The preneoplastic
lesions were categorized with respect to their sizes and
their areas of the occupied liver parenchyma. It was
observed that group B animals in which carcinogenesis
had been initiated with DENA and animals were sacrificed
Glycogen storage lesion shown after Digoxigenin-labeled  sense IGFII mRNA treatment during in situ hybridization  method ×100 Figure 7
Glycogen storage lesion shown after Digoxigenin-labeled 
sense IGFII mRNA treatment during in situ hybridization 
method ×100. Pv- portal vein. Bd – bile duct.
Section of hepatic tumor (shown by arrows) in HCC; using  toluedine blue ×40 Figure 8
Section of hepatic tumor (shown by arrows) in HCC; using 
toluedine blue ×40.
Section of hepatic tumor (shown by arrows) in HCC; using  PAS reaction ×40 Figure 9
Section of hepatic tumor (shown by arrows) in HCC; using 
PAS reaction ×40.
Section of hepatic tumor (shown by arrows) in HCC; IGFII  mRNA expression detected with DIG-labeled IGFII antisense  mRNA in tumor as well as peripheral tissue Figure 10
Section of hepatic tumor (shown by arrows) in HCC; IGFII 
mRNA expression detected with DIG-labeled IGFII antisense 
mRNA in tumor as well as peripheral tissue. ×40.Journal of Carcinogenesis 2005, 4:12 http://www.carcinogenesis.com/content/4/1/12
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after 8 weeks, had 81% focal lesions having size less than
1 mm i.e. smaller lesions and 19% focal lesions were in
the size range of 1 mm-3 mm. Group C had 52% lesions
less than 1 mm. 44% lesions were between 1 mm and 3
mm and sizes of 4% lesions were greater than 3 mm. In
group D animals, seven animals out of ten were found to
develop HCC (Table 2) and they had more intermediate
(1 mm-3 mm) and large (greater than 3 mm) lesions as
compared to smaller lesions.
When IGFII gene expressed, preneoplastic lesions were
compared to the various type of hepatic altered foci (HAF)
such as glycogen storage focal lesions, mixed cell focal
lesions, and basophilic focal lesions, it was found that
98% glycogen storage focal lesions expressed IGFII [Fig-
ures 5, 6, 7]. Again 74% of the mixed cell focal lesions
expressed IGFII where once again mainly glycogen storage
hepatocytes were found to express IGFII not the
basophilic cells. Very few basophilic cell focal lesions with
IGFII gene expression were detected. In those lesions,
there were, some glycogen containing cells (as seen with
PAS staining). As the lesions containing predominantly
basophilic cells, they were categorized under basophilic
lesions. Thus it may be believed that glycogen storage cells
showed IGFII expression in those basophilic lesions. Only
5% of the basophilic hepatic altered foci were found to
express IGFII although the results are statistically non-sig-
nificant. As described earlier in group D animals, seven
out of ten animals were found to develop HCC and they
had some high expression in the peripheral hepatocytes of
tumor. There was also some expression within the tumor
areas [Figures 8, 9, 10, 11].
Hepatocytes proliferation was established by demonstra-
tion of PCNA (Proliferating Cell Nuclear Antigen). PCNA
positive hepatocytes and non-hepatocytes were detected
in carcinogen treated groups as well as normal untreated
groups. Five fold higher numerical value of PCNA positive
cells was detected in the carcinogen treated animals as
compared to normal untreated animals (Table 3) and
PCNA positive cells in carcinogen treated animals were
mostly (about 85%) confined to lesion area. Interestingly
the counts were greater in glycogen storage lesions as well
as in HCC (data not shown). This indicates that prolifera-
tion was higher during the early stage i.e. at the immediate
post initiation stage as well as in HCC.
In the hepatic tissue of group D animals some scattered
spongiotic pericytoma have been noticed. This spongiotic
pericytoma are also believed to be the precursor of perisi-
nusoidal cell sarcomas [32]. They were very few in
numbers but were found in the hepatic tissue of all the
animals in group D. But they were not found in every
tissue slide of the same animals. When IGFII expression of
the subsequent slides were studied it was observed that
IGFII gene did not express in the area of spongiotic hepa-
tis. But high IGFII expression was noticed at the peripheral
hepatocytes [Figures 12, 13, 14, 15]. PCNA positive cells
were also detected predominantly in the peripheral cells
of spongiosis hepatis.
IGFII mRNA expression in hepatocytes in tumor area during  HCC in experimental animals (see protocols) ×97.5 Figure 11
IGFII mRNA expression in hepatocytes in tumor area during 
HCC in experimental animals (see protocols) ×97.5.
Table 3: Number of PCNA (Proliferating Cell Nuclear Antigen) positive liver cells per 103 cells
Labeling Indexa
Group HAF Hepatocytes Non focal-hepatocytes
Carcinogen-treated 667 ± 28* 122 ± 17*
Normal Control 132 ± 12 88 ± 14
a results show mean ± SD (n = 10)
* P < 0.001 as compared to normal control animals, assessed by Student's t-testJournal of Carcinogenesis 2005, 4:12 http://www.carcinogenesis.com/content/4/1/12
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Discussion
A predominant sequence of cellular changes starting from
the appearance of glycogenotic foci to the glycogen-poor
basophilic foci, leading to HCC via various mixed cell
populations, has been observed in rodents during the
development of HCC induced by various chemical carcin-
ogens, hormones, radiation, chronic viral infection and
transgenic manipulation [19,20]. During this process
several phenotypic changes appear which suggest a pro-
gressive cellular dedifferentiation.
The DIG detection system used here has been claimed to
offer a much higher sensitivity and detectability than
radioactive detection systems [33,34]. Using this system,
we tried to localize the IGF II gene expression in different
type(s) of foci during DENA-induced hepatocarcinogene-
sis. Predominant expression of the gene was located in
hepatic altered glycogen-storage foci which has been
claimed to be early preneoplastic lesions [32] along with
some expressions in foci of mixed cell populations. High
expression was also detected in HCC. It was higher at the
periphery as well as the glycogen storage cells of the
tumor. This observation is supported by the observation
of Sohda et.al who demonstrated that the localization of
IGF II mRNA in areas consisting of less differentiated
tumor were present at the periphery of the tumour nest
[35]. Higher expression was detected in the foci of
glycogen storage altered hepatocytes as compared to the
tumor cells. This suggests that there is a differential
expression of IGF II mRNA during the development of
preneoplasia to neoplasia. Fetal transcripts of IGF II
express high in man and rodent liver cancer [6]. In
human, fetal transcripts express highly in the HCC, sug-
gesting that IGF II-expression is late event during the
development of liver cancer [36]. On the other hand, an
inverse correlation was observed between IGF II-expres-
sion and cellular differentiation in rat [37]. Again, it has
been found that the IGF II expression is predominant at
Serial sections of experimental rat hepatic tissue showing spongiosis hepatis with haematoxylin and eosin (shown by white  arrows) ×40 Figure 12
Serial sections of experimental rat hepatic tissue showing spongiosis hepatis with haematoxylin and eosin (shown by white 
arrows) ×40.Journal of Carcinogenesis 2005, 4:12 http://www.carcinogenesis.com/content/4/1/12
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the fetal and neonatal life of rat and it declines with the
days after birth when IGF I is found to be increased and
believed to take up the role of IGF II [6]. Simultaneously
increased pattern of expressions of IGF I and TGFα, during
some preneoplastic and neoplastic conditions [35] also
suggests that the IGF I and TGFα may counterbalance the
activity of IGF II.
Amongst the various methods available, two important
methods of studying cancer cell proliferation are
measuring the rate of DNA synthesis and the immunohis-
tochemical reaction for proliferating cell nuclear antigen
(PCNA) [30,31]. Demonstration of PCNA has been
reported to be a valuable non-tracer method for the detec-
tion of proliferating cells. Report suggests the method is
used to detect proliferating cells in S phase, G2 and late
G1 phases of the cell cycles [32]. PCNA positive liver cell
counts were found to be significantly higher (p < 0.001)
in this study in carcinogen treated animals as compared to
normal control animals. Higher PCNA labeling index
were noticed in IGF II expressed lesions (mostly glycogen-
rich lesions) as compared to the other IGF II non-
expressed or little-expressed hepatic lesions (mixed cells
and basophilic cell lesions) in hepatic areas studied. This
suggests that the IGF II expressed cells in all the lesions are
more proliferating in nature as compared to the other
focal lesions and of course the extra-focal hepatic areas.
The labeling index was found to be higher again in HCC.
This indicates that cancer development is faster during
glycogen-rich focal development (they predominantly
expressed IGF II) and during the stage of HCC.
Spongiosis hepatis have been found interestingly only in-
group C animals (in six out of ten animals). They were
found to be very scattered in nature. In whole observation
they were only 18 in numbers (in 50 different hepatic tis-
sue samples of the seven animals of group C). Thus it
seems that they appear in progression phase of cancerous
process, at least during DENA-induced hepatocarcinogen-
esis. Spongiosis hepatis also described as spongiotic
pericytoma are believed to be the possible precursor of
malignant tumors [32]. It has also been classified as
Section of experimental rat hepatic tissue showing spongiosis hepatis with toluedine blue ×120 Figure 13
Section of experimental rat hepatic tissue showing spongiosis hepatis with toluedine blue ×120.Journal of Carcinogenesis 2005, 4:12 http://www.carcinogenesis.com/content/4/1/12
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perisinusoidal (ito) cell sarcomas [33]. Lesions classified
as spongiosis hepatis have been reported to progress to
pericytomas which have been related to perisinusoidal
cells (ito cells). Thus the study of these cells may help to
understand neoplastic transformation of them. In present
study efforts have been made to characterize various pre-
neoplastic hepatic altered foci and hepatic cellular carci-
noma along with spongiosis hepatis. Spongiosis hepatis
have been detected using haematoxylin and eosin, toluid-
ine blue and PAS staining. Consecutive sections were
compared with the IGFII expressions and it has been
observed that the predominant expression of IGFII were
noticed in the peripheral hepatocytes but not in the holes
of the spongiotic formations which are believed to be
filled with a finely flocculent material that shows meta-
chromasia (Acid mucopolysaccharide deposit) [32]. The
IGFII expression seems to be dominant more in the
peripheral hepatocytes of the spongiocyst hepatis. PCNA
positive cells were also detected in the surrounding areas
where the IGFII expressions were noticed. Again IGFII
expression has been claimed to be associated with the
development of hepatocellular carcinoma (HCC) by sev-
eral authors [34,35]. Thus the study further supports that
the spongiosis hepatis are possibly the origin of malignant
tumor [32]
The claims related to an amount of over expression of IGF
II gene in liver tumors and pre-neoplastic hepatic lesions
during hepatocarcinogenesis in animal models and in
human HCC were highly variable. A possible involvement
of an IGF II autocrine loop in the pathogenesis of hepatic
preneoplastic and neoplastic lesions have been linked
with the association of allelic imbalance with an increased
expression of the IGF II gene in pre-cancerous lesions
[36,42].
The work has demonstrated that the allelic imbalance of
the IGF II gene expression was seen in the early pre-cancer-
ous lesions during hepatocarcinogenesis; but was not
observed in well and moderately differentiated HCC.
Section of experimental rat hepatic tissue showing spongiosis hepatis with PAS reaction) ×40 Figure 14
Section of experimental rat hepatic tissue showing spongiosis hepatis with PAS reaction) ×40.Journal of Carcinogenesis 2005, 4:12 http://www.carcinogenesis.com/content/4/1/12
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Thus, some workers considered IGF II gene expression as
an early event. Mixed reports are found which claimed the
expression of IGFII either in preneoplasia [37,38] or
during HCC [34,35]. The over expression of IGF II in HCC
has been claimed to be associated with re-expression pat-
tern of IGF II transcript occurring through activation of
fetal promoters p2 – p4 with a loss of activity of the adult
promoter p1 [36]. Interestingly, the over expression of IGF
II was found in the preneoplastic glycogen storage focal
lesions maximally as compared to that in the basophilic
lesions.
In mixed cell focal lesions as well as basophilic lesions,
the expressions were low and in the mixed cell focal
lesions the expression was particularly confined to the gly-
cogen rich cells. When the expression was predominant
almost throughout a lesion, this has been considered as
an IGF II expressed lesion in this study. So, the trend of
IGF II over expression in our study was in the sequence of
"high-low-high" in "glycogen storage foci – mixed cell foci
– basophilic lesion – HCC". This suggests that the IGF II
over expression is not only the early event, but the late
event too. The gene expression amongst others appears to
be responsible for cancer initiation process as well as in
the progression of HCC. But its role during the progres-
sion from preneoplasia to neoplasia remains to be eluci-
dated. Thus this gene over expression or may be the
protein over expression can be used to detect the cancer at
the early stage or at HCC and hence it may be considered
as a future diagnostic means for detection of hepatic can-
cer and its stages and IGFII gene 33 expression could be
considered as one of the best positive markers for early
detection of putative preneoplastic cell as well as HCC in
chemically induced hepatocarcinogenesis. Further investi-
gation of this gene expression is warranted in the interest
of better cancer detection. Thus this may lead to better
cancer prevention. Again in contrast to many other gene
or protein expressions IGFII has particular advantage for
IGFII mRNA expression detected by DIG- labeled antisense IGFII mRNA in the peripheral cells of the spongiocyst hepatis ×120 Figure 15
IGFII mRNA expression detected by DIG- labeled antisense IGFII mRNA in the peripheral cells of the spongiocyst hepatis 
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its use in screening of potential carcinogens and promot-
ers since it is not expressed in lesions with some non-
xenotoxic chemicals [39]. Further IGFII gene was reported
to express at high levels in both spontaneous [40] and
induced [41] hepatic lesions at the early stages of develop-
ment [37,38] and in HCC [32,33].
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